CRIS
Scientific
Symposium
& Awards
Scientific
Symposium
& Awards
00
Days
00
Hrs
00
Min
April 10, 2025 | 10:00h.
CRIS believes that research is the only path to developing new treatments that provide hope for patients who currently have no effective options.CRIS supports scientific programmes, fellowships, and specialized cancer units to support cutting-edge cancer research, with a focus on innovative strategies. Through this CRIS Symposium, the foundation creates a collaborative space for scientists to share knowledge, inspire one another, and work together towards conquering cancer.
Symposium
April 10, 2025
10:00h.
Madrid
10:00h.
Madrid
The CRIS Symposium on Cancer Biomarkers is a crucial event, addressing one of the most important areas in cancer research today. Biomarkers are transforming cancer diagnosis and treatment, paving the way for personalized therapies.
With rapid technological advances, it is essential for researchers, clinicians, and stakeholders to come together to share findings and collaborate on new ideas.
This symposium emphasizes the importance of a multidisciplinary approach, bringing together and clinical researchers to discuss both the potential and the challenges of bringing biomarkers into clinical practice. By fostering collaboration across disciplines, this forum aims to push the boundaries of precision oncology and advance treatments for patients who currently have limited options.
Why Assist
The CRIS Symposium on Cancer Biomarkers is a crucial event, addressing one of the most important areas in cancer research today. Biomarkers are transforming cancer diagnosis and treatment, paving the way for personalized therapies.
This event brings together leading experts, emerging researchers, clinicians, healthcare professionals, and patients to explore the latest advancements in biomarkers and their clinical applications. The symposium emphasizes the real-world impact of research and highlights the importance of collaborative approaches to solving pressing challenges in oncology. Whether you are a seasoned expert, an aspiring researcher, or a patient advocate, this forum provides invaluable insights and networking opportunities that can accelerate progress in the fight against cancer.
Agenda
Frontiers in cancer biomarkers:
Pioneering innovation and clinical impact
Pioneering innovation and clinical impact
An International Forum for Advancing Biomarker Research and Application.
The event will be structured in sessions combining keynote lectures and short talks by young researchers to encourage the exchange of knowledge, foster collaborations and integrate new generations with leading researchers in their fields.
The event will be structured in sessions combining keynote lectures and short talks by young researchers to encourage the exchange of knowledge, foster collaborations and integrate new generations with leading researchers in their fields.
9:15
Registry and Welcome
10:00
Introduction of the Event and words by the CRIS President
10:15
SESSION 1:
10:15
Keynote Talk 1 (40’ + 10’ questions): Paul Mischel (Stanford University, Stanford, USA)
11:05
Short Talk 1 (10’ + 5’ questions): Lorea Valcárcel (Universidad del País Vasco, Bilbao)
11:20
Short Talk 2 (10’ + 5’ questions): Alejo Rodríguez Fraticelli (IRB, Barcelona)
11:35
COFFEE BREAK
12:00
SESSION 2:
12:00
Keynote Talk 2 (40’ + 10’ questions): Alice Shaw (Dana Farber Cancer Institute, Boston, USA)
12:50
Short Talk 3 (10’ + 5’ questions): Aleix Prat (Hospital Clínic, Barcelona)
13:05
Short Talk 4 (10’ + 5’ questions): Eleni Louka (Oxford University, Oxford)
13:30
LUNCH – CATERING
14:30
SESSION 3:
14:30
Keynote Talk 3 (40’ + 10’ questions): James Gulley (National Cancer Institute, USA)
15:20
Short Talk 5 (10’ + 5’ questions): Rebeca González Guerrero (Centre Méditerranéen de médecine moléculaire, Nice)
15:35
Short Talk 6 (10’ + 5’ questions): Ana Jiménez Ubieto (Hospital 12 de Octubre, Madrid)
16:00
Round table with keynote speakers (40’). Moderator: Christine Hodgdon (GRASP, USA)
16:45
One-on-One Sessions
18:00
CLOSURE
19:00
CRIS Research Programmes Award Ceremony
Speakers
Paul Mischel
Stanford University
Paul S. Mischel, M.D., is the Fortinet Founders Professor, and Vice Chair for Research for the Department of Pathology, Stanford Medicine, an Institute Scholar in Sarafan ChEM-H. He is also a Faculty Advisor for Experimental Biology at the Innovative Medicines Accelerator at Stanford University. Mischel is a physician scientist whose research on extrachromosomal DNA (ecDNA) has catalysed a paradigm shift in our understanding of cancer. Mischel leads Team eDyNAmiC, an international team that received a $25M Cancer Grand Challenges Award from Cancer Research UK and the National Cancer. Mischel is a member of the National Academy of Medicine and recipient of the 2023 Ernst W. Bertner Memorial Award from MD Anderson for Distinguished Contributions to Cancer Research. Mischel is also an elected Fellow and Past-President of the American Society for Clinical Investigation, and an elected Fellow of the American Association of Physicians and The American Association for the Advancement of Science.
Read more →
Alice Shaw
Dana Farber Institute
Alice Shaw has made key contributions to the field of biomarkers, especially in lung cancer, where she identified mutations in ALK and ROS1 as therapeutic targets. With a career spanning both academia and industry, Shaw brings a unique perspective on how to translate biomarkers from research to clinical practice. Her experience as global head of translational clinical oncology at Novartis is key to guiding the development of personalized therapies, integrating biomarker advances with clinical development needs.
Read more →
James Gulley
Director, Medical Oncology Service, National Cancer Institute (NCI), USA
He is a pioneer in the development of immunological biomarkers, particularly those related to the response of the immune system to vaccine and T-cell based therapies. He has worked on the identification of biomarkers that predict the efficacy of immunotherapies, allowing better selection of patients who will respond to these treatments. His clinical trials have contributed to validate biomarkers that guide the personalization of immunotherapeutic treatments in advanced cancers.
Read more →
Lorea Valcárcel
Ikerbaske and Ramón y Cajal Research Fellow, University of the Basque Country (UPV/EHU), Bilbao
Dr. Lorea Valcárcel studies the prostate cancer tumor microenvironment and its influence in tumor aggressiveness. Her research examines the interactions between cancer cells and stromal components, aiming to identify novel therapeutic targets and biomarkers. Her potential was recognized with the CRIS Emerging Leader Programme, to continue employing advanced techniques to explore the heterogeneity within prostate tumors.
Read more →
Alejo Rodríguez Fraticelli
Group Leader of the Quantitative Stem Cell Dynamic, Barcelona Research Institute (IRB), Barcelona.
Dr. Alejo Fraticelli team focuses their research on stem cell memory and epigenetics in haematopoiesis, immunity, and leukaemia. Dr. Rodríguez-Fraticelli's lab employs advanced methods for lineage tracing to study these biological processes. He was awarded the prestigious CRIS Excellence grant to study leukemia stem cells and their role in relapse. Dr. Rodríguez-Fraticelli aims to uncover innovative therapeutic strategies that could transform treatment approaches for acute myeloid leukaemia patients.
Read more →
Aleix Prat
Director Institut of Oncology at Hospital Clínic, Barcelona
Dr. Prat is the Director Hospital Clinic´s Cancer and Blood Disorders Institute in Barcelona (Spain), Professor of Medicine at the University of Barcelona (UB) and Head of the Translational Genomics and Targeted Therapeutics in Solid Tumors Group at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). Furthermore, Dr. Prat is the Head of the Breast Cancer program at IOB-QuironSalud. In 2022, he co-founded the spin-off company called Reveal Genomics, which has developed the HER2DX® diagnostic genomic test recognized by TIME as one of the best inventions of 2022. Dr. Prat also directs the Chair of Innovation in Precision Oncology at the UB where he is a professor. Over his career, Dr Prat has obtained world-wide recognition as a prestigious clinical scientist in the field of breast cancer, genomics, and biomarker and drug development. He has actively participated in >300 peer-reviewed articles, and he has supervised several PhD students
Read more →
Eleni Louka
Director, Academic Clinical Lecturer in Paediatric Haematology at the University of Oxford, UK
Dr Eleni Louka is an expert in childhood blood disorders, particularly paediatric myelodysplastic syndromes and myeloproliferative disorders. She combines clinical work with laboratory research, aiming to translate scientific discoveries into improved patient care and novel therapeutic approaches for paediatric haematological conditions. To deepen further her research on these tumors, CRIS and the University of Oxford awarded Dr. Louka with the CRIS-Oxford Cancer Academic Clinician Post-doctoral Fellowship.
Read more →
Rebeca González Guerrero
Researcher at the Centre Méditerranéen de Médecine Moléculaire (C3M) in Nice, France.
Dr. González Guerrero is associated with Institute of Neurosciences of Alicante (CSIC-Universidad Miguel Hernández), and an awardee of the CRIS Out-Back Programme, that grants young promising researchers with an abroad post-doc and ensures their comeback to Spain. She employs advanced techniques to investigate the complex interactions between melanoma tumors and the immune system. Her research aims to uncover mechanisms of therapy resistance and identify novel strategies to enhance immunotherapy efficacy in melanoma treatment.
Read more →
Ana Jiménez Ubieto
Associate Hematologist, Hospital 12 de Octubre, Madrid
Dr. Jiménez Ubieto’s work focuses on haematological malignancies, particularly lymphomas. Dr. Jiménez Ubieto is involved in clinical research aimed at improving treatment strategies for patients with various types of lymphoma. She has participated in several practice-changing clinical trials for follicular lymphoma, contributing to advancements in treatment strategies. She was awarded with the CRIS Translational Physician Programme to further improve the follow-up and treatment of follicular lymphoma patients. She collaborates with multidisciplinary teams to conduct clinical trials and translational research, contributing to the advancement of personalized medicine approaches in lymphoma therapy.
Read more →
Awards
CRIS Research Programmes Awardees 2024.
CRIS Science Day 2024.
CRIS Science Day 2024.
The CRIS Research 2025 Award Ceremony is an event that celebrates research brilliance and excellence as a driver for advancing cancer strategies. CRIS promotes cancer research by supporting excellent quality projects, providing them with exceptional funding and a competitive duration. This ceremony will recognize the researchers awarded in the different CRIS calls, both nationally and internationally. In addition, there will be a formal renewal of CRIS Research Units in Spanish public hospitals
CRIS Excellence Programme
Guadalupe Sabio
- Spanish Oncology Research Center (CNIO), Madrid
- CRIS Liver Cancer Project
Biola Javierre
- Josep Carreras Leukemia Research Institute
- CRIS Leukemia Resistances Project
CRIS Physician Scientist Programme
Laura Mezquita
- Hospital Clínic / IDIBAPS, Barcelona
- CRIS Project on Environmental Factors in Lung Cancer
Jenniffer Linares
- Institut d’Investigacions Mèdiques Hospital del Mar
- CRIS Colon Cancer Microenvironment Project
CRIS Emerging Leader Programme:
Luis Francisco Lorenzo
- Centro de Investigación del Cáncer (CIC), Salamanca
- CRIS Project on Advanced Colon Cancer Models
Francisco Martínez
- Vall d’Hebrón Institute of Oncology (VHIO)
- CRIS Project on Liver Cancer Metastasis
CRIS Out-Back Programme:
Están en la institución “Out”,
Están en la institución “Out”,
Elia Seguí Solís
- Dana-Farber Cancer Institute / IDIBAPS – Hospital Clínic
- RIS Project on Immunotherapy in Breast Cancer
Virginia Laspidea
- Stanford University / Josep Carreras Leukemia Research Institute
- Proyecto CRIS de CAR-T contra Metástasis
CRIS - Gustave Roussy Real Life Trials in Oncology:
El año pasado recogió el investigador de España
El año pasado recogió el investigador de España
Patrica Pautier (I. Gustave Roussy), César Serrano (VHIO)
- Institute Gustave Roussy , Paris / Vall d’Hebrón Institute of Oncology
- Ensayo BRAVA
CRIS-Princess Margaret Cancer Centre Drug Development Fellowship Programme:
Grégoire Marret
- Institute Curie París
CRIS-ASEICA Dual training in Medical Residency-PhD in Cancer:
Clara Castro Carballeira
- Hospital Universitario Marqués de Valdecilla, Santander
CRIS Training and Mobility fellowships in collaboration with Medical Societies:
Representante de becas.
Representante de becas.
Marina Gómez Llobell
- Beca Estancia SEHH.
- Hospital Universitario Gregorio Marañón.
CRIS FIGHT KIDS CANCER
Representante de los galardonados de Fight Kids.
Representante de los galardonados de Fight Kids.
Adriana Sánchez Danés
- Champalimaud Foundation, Lisboa.
- FIGHT4MB en Meduloblastoma Infantil.
EXTRAORDINARY PROFFESSORSHIP CRIS / Universidad Complutense
Subirán en grupo y hablará una representante. Todas son en Madrid.
Subirán en grupo y hablará una representante. Todas son en Madrid.
Raquel Paseiro Puchol
María Moya Gómez
Adela Querencias Martínez
María Teruel Arrazola
Sofia Leal Lassalle
Sara Gallardo García
Carlota Cantelar Rodríguez
Alejandra Jiménez García
Alfonso Hermoso Vela
Blanca Urbelz López-Puertas
María García Mulero
María Moya Gómez
Adela Querencias Martínez
María Teruel Arrazola
Sofia Leal Lassalle
Sara Gallardo García
Carlota Cantelar Rodríguez
Alejandra Jiménez García
Alfonso Hermoso Vela
Blanca Urbelz López-Puertas
María García Mulero
RENEWAL OF UNITS CRIS:
Unidad CRIS de Terapias Avanzadas en Cáncer Infantil.
Unidad CRIS de Terapias Avanzadas en Cáncer Infantil.
Dr. Antonio Pérez
- Hospital Universitario de la Paz, Madrid.
FAQ
Who is the CRIS Symposium on Cancer Biomarkers aimed at?
How can I register for the event, and what is the registration fee?
Will the symposium be available online for those unable to attend in person?
In what language will the presentations and sessions be conducted?
Will attendees receive a certificate of participation for the symposium?
Can attendees earn academic or professional credits for attending the symposium?
What networking opportunities will be available during the event?
How do I sign up for the one-on-one sessions?
What specific topics will be covered in the symposium sessions?
Will there be any social activities or dinners for attendees?
Where is the event venue located, and what transportation options are available?
April 10, 2025
In collaboration with
